Patents by Inventor Masako Ura

Masako Ura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8022047
    Abstract: A cancer therapeutic agent comprising a combination of compound A described below, or a pharmaceutically acceptable salt thereof, and compound B described below, or a pharmaceutically acceptable salt thereof: Compound A represented by the formula of claim 1 and Compound B represented by: at least one type of compound selected from the group consisting of a platinum-type anticancer compound, selected from the group consisting of cisplatin carboplatin, oxaliplatin and nedaplatin; a gemcitabine-type compound, selected from the group consisting of gemcitabine and Ara-C; a 5-FU-type compound, selected from the group consisting of 5-FU, doxifluridine, UFT, carmofur, S-1, and capecitabine; a texane-type compound, selected from the group consisting of Taxol, Taxotere, IDN 5109, BMS 188797 BMS 184476 paclitaxel and docetaxel; a vinca alkaloid-type compound, selected from the group consisting of vinorelbine, vincristine, vinblastine, and videsine; an anticancer tyrosine kinase inhibitor compound, and an anticancer mo
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: September 20, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Mika Endo, Masako Ura
  • Publication number: 20090149478
    Abstract: A cancer therapeutic agent according to the present invention comprises a combination of compound A described below, or a pharmaceutically acceptable salt thereof, and compound B described below, or a pharmaceutically acceptable salt thereof: Compound A: compound A1 represented by formula (1) below, or water-soluble prodrug A2 thereof; Compound B: at least one type of compound selected from the group consisting of a platinum-type anticancer compound, a gemcitabine-type compound, a 5-FU-type compound, a taxane-type compound, a vinca alkaloid-type compound, an anticancer tyrosine kinase inhibitor compound, and an anticancer monoclonal antibody; (wherein, R11 represents a hydrogen atom, a halogen atom or a C1-C6 alkyl group; R12 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, or a hydroxyl group; R21 represents a hydrogen atom or a C1-C10 alkyl group which may comprise one to three substituents selected from Group B described below: Group B: a C1-C6 alkoxy group, a hydroxy group,
    Type: Application
    Filed: August 22, 2006
    Publication date: June 11, 2009
    Inventors: Mika Endo, Masako Ura
  • Publication number: 20090118271
    Abstract: Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer of the present invention comprise a water-soluble prodrug represented by formula 1 described below, or a pharmaceutically acceptable salt, or a hydrate or solvate of the prodrug or pharmaceutically acceptable salt, (wherein, R1 represents a hydrogen atom, or a C1-C6 alkyl group; W represents a divalent group comprising a tertiary amino group or a divalent group comprising a sulfonyl group, and Y represents a residue of a compound represented by Y—OH comprising an alcoholic hydroxyl group, wherein said Y—OH is a camptothecin, a taxane, or an anticancer nucleotide).
    Type: Application
    Filed: October 19, 2006
    Publication date: May 7, 2009
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Isao Umeda, Jun Ohwada, Sawako Ozawa, Mika Endo, Masako Ura